Market Cap 147.10B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.33
Forward PE 8.66
Profit Margin 12.42%
Debt to Equity Ratio 0.71
Volume 51,074,400
Avg Vol 44,029,770
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 100%
Beta 0.34
Analysts Sell
Price Target $28.77

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
Latest News on PFE
Pfizer price target lowered to $31 from $35 at Guggenheim

2026-08-07T11:40:49.000Z - 2 hours ago

Pfizer price target lowered to $31 from $35 at Guggenheim


Pfizer’s (PFE) Q2 Earnings Support a Bullish View

2026-08-06T13:09:00.000Z - 1 day ago

Pfizer’s (PFE) Q2 Earnings Support a Bullish View


Pfizer price target raised to $27 from $26 at BofA

2026-08-05T10:45:23.000Z - 2 days ago

Pfizer price target raised to $27 from $26 at BofA


Pfizer Earnings Call Transcript: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 3 days ago

Pfizer Earnings Call Transcript: Q2 2026


Pfizer Earnings release: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 3 days ago

Pfizer Earnings release: Q2 2026


Pfizer Slides: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 3 days ago

Pfizer Slides: Q2 2026


Pfizer Quarterly report: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 3 days ago

Pfizer Quarterly report: Q2 2026


Pfizer Post Loss on Higher Revenue

Aug 4, 2026, 7:24 AM EDT - 3 days ago

Pfizer Post Loss on Higher Revenue


Pfizer reports Q2 adjusted EPS 77c, consensus 68c

2026-08-04T10:52:17.000Z - 3 days ago

Pfizer reports Q2 adjusted EPS 77c, consensus 68c


Pfizer says LITFULO studies meet co-primary endpoints

2026-07-30T11:03:18.000Z - 8 days ago

Pfizer says LITFULO studies meet co-primary endpoints


FDA grants priority review for Pfizer’s Talzena plus Xtandi

2026-07-22T20:40:37.000Z - 15 days ago

FDA grants priority review for Pfizer’s Talzena plus Xtandi


Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jul 6, 2026, 10:00 AM EDT - 4 weeks ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low


Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 6 weeks ago

Pfizer Declares Third-Quarter 2026 Dividend


Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 6 weeks ago

Pfizer dismissed from US states' drug price-fixing lawsuit


Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 7 weeks ago

Pfizer CFO Dave Denton to step down, leave company in August


Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 7 weeks ago

Pfizer Announces Chief Financial Officer Transition


US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 2 months ago

US FDA approves Pfizer's bleeding disorder drug for children


Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Transcript: Study update


Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Slides: Study update


Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Press release: Study update


Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 2:00 PM EDT - 2 months ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026